Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Comparison of Iodide-125 and Ruthenium-106 Brachytherapy in the Treatment of Choroidal Melanomas Publisher



Ghassemi F1, 2, 3 ; Sheibani S4 ; Arjmand M3 ; Poorbaygi H4 ; Kouhestani E1 ; Sabour S5 ; Samiei F6 ; Beikiardakani A7 ; Jabarvand M1 ; Tari AS1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran
  2. 2. Retina & Vitreous Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran
  3. 3. Ocular Oncology Service, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, IR, Iran
  4. 4. Radiation Application Research School, Nuclear Science and Technology Research Institute, Tehran, Iran
  5. 5. Safety Promotion and Injury Prevention Research Centre, Department of Clinical Epidemiology, School of Health, Shahid Beheshti University of Medical Sciences, Tehran, IR, Iran
  6. 6. Radiation Oncology Department, Cancer Institute, Imam Hospital and Medical Complex, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Radiation Physics Department, Princess Margaret Hospital, Toronto, ON, Canada

Source: Clinical Ophthalmology Published:2020


Abstract

Background: To compare iodine-125 (125I) with ruthenium-106 (106 Ru) episcleral plaque radiation therapy in terms of the effectiveness and non-inferiority for choroidal melanoma treatment. Objective: To report the non-inferiority of new made iodine-125 (125I) compared with ruthenium-106 (106 Ru) episcleral plaque radiation. Patients and Methods: A retrospective, non-randomized comparative case series. In this series the patients treated with125 I and106 Ru episcleral plaques for choroidal melanoma between September 2013 and August 2017 at Farabi Hospital are compared. Local control of choroidal melanomas after125 I and106 Ru plaques implantation and vision changes are the main outcome measures. Results: A total of 35 patients were identified (125I = 15,106Ru = 20). No significant difference between two groups in visual acuity, diameter and thickness changes were observed after treatment. Multivariate linear regression (MLR) analysis showed that final diameter was only, independently and significantly, correlated with the pre-treatment diameter of the tumor (β = 0.59, 95% confidence interval [CI]: 0.29, 1.34, P = 0.003). The same MLR analysis for the final thickness and visual acuity, after adjusting for age and sex showed no significant difference between two groups. A single patient treated with106Ru had local tumor recurrence with no one in the125 I group. No statistical difference in the rate of ocular complications was observed. Conclusion: The treatment with our125 I plaques is as effective as106 Ru plaques in controlling choroidal melanoma tumor and preserving the vision during the two and half year of follow-up. The complication rates are alike. It means that the effectiveness of125I is not only comparable to106Ru but also superior when the outcome of the interest is the thickness of the tumors. © 2020 Ghassemi et al.
Related Docs
1. Ruthenium-106 Brachytherapy for Thick Uveal Melanoma: Reappraisal of Apex and Base Dose Radiation and Dose Rate, Journal of Contemporary Brachytherapy (2016)
2. Ruthenium-106 Plaque Radiotherapy for Uveal Melanoma: Analysis of Tumor Dimension and Location on Anatomical and Functional Results, BMC Ophthalmology (2022)
3. Evolution of Dose Distribution for a 125I Eye Plaque Using Mcnpx and Plaque Simulator Software, Precision Radiation Oncology (2024)
4. Hydrogen Nanobubbles: A Novel Approach Toward Radio-Sensitization Agents, Medical Physics (2023)
5. Pediatric Ocular Melanoma: A Collaborative Multicenter Study and Meta-Analysis, Journal of AAPOS (2023)
6. Uveal Melanoma in the Iranian Population: Two Decades of Patient Management in a Tertiary Eye Center, International Journal of Retina and Vitreous (2024)
Experts (# of related papers)
View all Related Experts
Fariba Ghassemi (3)
Babak Masoomian (2)